Produced with support from National Institute on Drug Abuse (NIDA) and National Institute on Alcohol Abuse and Alcoholism (NIAAA) National Institutes of Health U.S. Department of Health & Human Services
Stem-cell pioneer bows out doi:10.1038/479459a Geron halts first-of-its-kind clinical trial for spinal therapy. Full Text
Preemptive genotyping trialed to prevent adverse drug reactions doi:10.1038/nm1111-1323 Schemes to couple a patient’s genetic information to effective intervention strategies could avoid serious adverse drug reactions. Full Text
First drugs found to inhibit elusive cancer target doi:10.1038/nm1111-1325 Buoyed by the promising therapeutic effects in mice with several types of cancer of JQ1, a small molecule that inhibits bromodomain protein 4 and thereby indirectly prevents MYC expression, companies are racing to test the molecules in clinical trials. Full Text
Hepatitis C: move over interferon doi:10.1038/nbt.2031 Following approval of hepatitis C virus protease inhibitors Incivek and Victrelis, companies are partnering to devise all-oral combination antiviral regimens without interferon alpha. But the virus is a long way from vanquished. Full Text
Dampening neuroinflammation doi:10.1038/scibx.2011.1254 Researchers have shown that a small molecule inhibitor of monoacylglycerol lipase reduces neuroinflammation in a mouse model of Parkinson's disease, and are studying the compound in other neurodegenerative and neurological diseases. Newco Abide Therapeutics is exercising an option to license these inhibitors. Full Text
Vemurafenib doi:10.1038/nrd3579 In August 2011, vemurafenib, an inhibitor of BRAF kinase, was approved by the US Food and Drug Administration for the treatment of patients with unresectable or metastatic melanoma with the BRAFV600E mutation. Full Text
The depression market doi:10.1038/nrd3585 This article outlines the existing therapies and key drugs that have recently been launched or are in clinical development for the treatment of major depressive disorder, a disorder for which fewer than half of patients currently receive drug treatment. Full Text
Inflammatory diseases: Stopping monocytes in their tracks doi:10.1038/nrd3590 A recently described method for specifically targeting inflammatory monocyte migration attenuates disease severity in mouse models of a number of inflammatory conditions. Full Text
Lead identification: Keeping tetramers together doi:10.1038/nrd3586 A new study has identified several drug candidates that inhibit the first step in amyloid formation by preventing the dissociation of transthyretin tetramers. Full Text
Neurodevelopmental disorders: Mice that mirror autism doi:10.1038/nrn3129 Mice lacking Cntnap2 show abnormal neuronal migration, asynchronous firing patterns and have an autism-like phenotype that can be partially normalized by treatment with risperidone. Full Text
Quantifying factors for the success of stratified medicine doi:10.1038/nrd3557 Co-developing a drug with a diagnostic presents challenges for product developers, regulators, payers and physicians. This article uses data from case studies, coupled with modelling of clinical outcomes and economic value, to quantify the effects of decisions on key issues such as clinical trial design. Full Text
Targeting protein prenylation for cancer therapy doi:10.1038/nrc3151 This article outlines the mechanisms by which inhibitors of farnesyltransferase and geranylgeranyltransferase 1 are expected to confer anticancer effects, and strategies to overcome the overall lack of success of these agents in clinical trials compared with their preclinical efficacy. Full Text
Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity doi:10.1038/nbt.2017 Anastassiadis et al. used functional assays to profile the activities of 178 commercially available kinase inhibitors against 300 recombinant human protein kinases, revealing complex and often unexpected interactions between protein kinases and kinase inhibitors. Full Text
Comprehensive analysis of kinase inhibitor selectivity doi:10.1038/nbt.1990 By profiling the binding of 72 kinase inhibitors to 442 human kinase catalytic domains, Davis et al. have uncovered group-specific differences in selectivity and suggest the feasibility of developing reasonably specific inhibitors for most kinases. Full Text
Career snapshots archive Career snapshots feature people associated with drug discovery and drug development, with the aim of providing expert insights and advice on a wide range of positions and career paths in this field. Full Text
SciBX: Science-Business eXchange is a weekly publication that identifies and analyzes the most important translational research articles from over 40 journals. Find out which papers have real scientific and commercial potential, and why.
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com
You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant)
Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA
Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston
Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS.
No comments:
Post a Comment